INVIVYD INC. - COMMON

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

13 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

12 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

12 Sep 2022 06:15:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces Corporate Name Change to Invivyd

12 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

06 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

15 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

05 Jul 2022 06:25:58 By Nasdaq GlobeNewswire

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors

01 Jul 2022 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports First Quarter 2022 Financial Results

13 May 2022 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request

14 Apr 2022 06:45:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

30 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics, Inc. Announces 2022 Annual Meeting of Stockholders

18 Mar 2022 17:33:15 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer

23 Feb 2022 15:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

22 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces CEO Succession Plan

18 Feb 2022 18:33:28 By Nasdaq GlobeNewswire

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

12 Jan 2022 15:56:55 By Nasdaq GlobeNewswire

Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

06 Jan 2022 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant

14 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

29 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19

22 Nov 2021 05:30:00 By Nasdaq GlobeNewswire